Memantin Stada (Memantine Hydrochloride)

Memantine hydrochloride works by binding to the NMDA‑type glutamate receptor at a site distinct from the glutamate binding site. This non‑competitive antagonism reduces excessive calcium influx during pathological overstimulation, limiting excitotoxic neuronal damage while preserving normal synaptic activity.

The dosage of Memantin Stada is determined by the prescribing clinician based on the patient’s clinical condition, renal function, and tolerability. The prescriber will select the appropriate strength and titration schedule according to current medical guidelines.

Safety data for Memantin Stada during pregnancy and lactation are limited, and the pregnancy category is listed as unknown. Healthcare providers must weigh potential benefits against possible risks before prescribing to pregnant or nursing women.

To order Memantin Stada, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Memantin Stada belongs to the NMDA antagonist class, whereas drugs such as donepezil, rivastigmine and galantamine are cholinesterase inhibitors. Memantine is typically used in moderate to severe disease and may be combined with a cholinesterase inhibitor for broader symptomatic coverage.

Memantin Stada tablets should be stored below 25 °C in their original packaging, protected from moisture and direct sunlight. Keep the product out of reach of children and avoid exposing it to excessive heat or humidity.

Memantin Stada is taken orally, usually as a tablet swallowed whole with water. It is commonly initiated at a low dose and titrated upward as directed by the prescriber to achieve the therapeutic target while monitoring tolerance.

Serious adverse events include seizures, severe allergic reactions such as rash or angioedema, hallucinations or psychosis, marked hypertension, and significant liver enzyme elevations. Patients should seek immediate medical attention if any of these symptoms develop.

Memantin Stada should be avoided in patients with known hypersensitivity to memantine or any excipients in the tablet. Caution is advised for individuals with uncontrolled seizures, severe renal impairment, or those taking other NMDA antagonists, as the risk of adverse CNS effects may be heightened.